NAD+ precursor research in Canada compares three main approaches to raising intracellular NAD+ levels: direct NAD+ supplementation, nicotinamide mononucleotide (NMN), and nicotinamide riboside (NR). Each enters the NAD+ biosynthesis pathway at a different point, has different pharmacokinetics, and faces different bioavailability challenges. Canadian aging biology and metabolic researchers study these three compounds to understand which is most effective at raising specific tissue NAD+ levels and which downstream pathways are most robustly activated.
NAD+ Direct Supplementation
Direct NAD+ has high molecular weight and poor cell membrane permeability, requiring active transport mechanisms. Research suggests that orally administered NAD+ is largely degraded to nicotinamide before absorption. However, injectable NAD+ research bypasses gut degradation and achieves higher plasma NAD+ levels. Canadian researchers study injectable NAD+ for acute elevation of blood NAD+ and downstream PARP and sirtuin activation.
NMN Research
NMN enters cells via the Slc12a8 transporter and is phosphorylated to NAD+ inside the cell. Canadian researchers study NMN for its ability to raise NAD+ in specific tissues including the gut, liver, and muscle. NMN has a higher molecular weight than NR but more direct conversion to NAD+ without nicotinamide intermediate accumulation.
NR Research
Nicotinamide riboside enters cells via ENT transporters and is phosphorylated to NMN then NAD+. NR is well-studied and has good oral bioavailability data in Canadian research. It raises plasma NAD+ metabolites dose-dependently and activates sirtuin SIRT1/SIRT3 pathways in research models.
Sourcing NAD+ in Canada
Research-grade injectable NAD+ is available from EhBuddy Peptides in Canada. Lab-tested for purity. For laboratory research use only.
The NAD+ precursor research landscape in Canada is rapidly evolving, with each form offering distinct pharmacokinetic and mechanistic advantages for different research applications.
